PMA device
Symplicity Spyral Renal Denervation System
Medtronic, Inc. · Ablation Catheter, Renal Denervation (QYI, Class III) · First FDA decision Nov 17, 2023, newest Sep 10, 2026High blood pressure (hypertension)
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
12
Naming "Symplicity Spyral"
MAUDE reports
24
Brand "Symplicity Spyral", since 2015
PubMed studies
35
Mentioning "Symplicity Spyral"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Symplicity Spyral Renal Denervation System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Symplicity Spyral Renal Denervation SystemPMA supplement
P220026-S014 · Decided Sep 10, 2026 · 225 days after receipt · Normal 180 Day Track No User Fee
Device type: Ablation catheter, renal denervation (QYI) · Cardiology
- Symplicity Spyral Renal Denervation SystemBreakthroughPMA
P220026 · Decided Nov 17, 2023 · 374 days after receipt
Device type: Ablation catheter, renal denervation (QYI) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Renal Denervation for Uncontrolled HypertensionNational analysisReview closedCAG-00470NUpdated Sep 22, 2026
- Renal Denervation (RDN) for Uncontrolled HypertensionNational determinationOn the books20.40Updated Mar 24, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Symplicity Spyral", any status and sponsor, newest update first.
Medtronic VascularPublic (MDT)
NCT07174622 · 1,000 participants (planned) · Start Oct 28, 2025 · Primary completion Jun 2029
Device: Renal Denervation (Symplicity Spyral™) · For: Hypertension; Cardiovascular Diseases; Vascular Diseases
Sites: Boston, Massachusetts
- SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTNActive, not recruiting
Medtronic VascularPublic (MDT)
NCT05198674 · 1,899 participants · Start Oct 20, 2021 · Primary completion Mar 5, 2026
Device: Renal Denervation (Symplicity Spyral™) · For: Hypertension; Vascular Diseases; Cardiovascular Diseases and 2 more
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 97 sites in all
Medtronic VascularPublic (MDT)
NCT07115953 · 130 participants (planned) · Start Sep 22, 2025 · Primary completion Oct 30, 2027
Device: Symplicity Spyral™ multi-electrode renal denervation system · For: Hypertension; Vascular Diseases; Cardiovascular Diseases and 2 more
Sites: Melbourne, Australia; Perth, Australia; Genk, Belgium · 21 sites in all
9 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Symplicity Spyral", and for the whole product code for context.
This brand
24 reports: 8 malfunction, 16 injury, 0 death
Whole product code QYI
47 reports: 13 malfunction, 33 injury, 0 death
Newest reports for this brand
9612164-2026-05001 · Received Oct 6, 2026 · Event dated Sep 10, 2026
Device type: Ablation Catheter, Renal Denervation (QYI)
Device problem as coded: Failure to Cycle; Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hematoma; Hemorrhage/Blood Loss/Bleeding; Pain
9612164-2026-04338 · Received Aug 27, 2026 · Event dated Sep 23, 2025
Device type: Ablation Catheter, Renal Denervation (QYI)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Stroke/CVA; High Blood Pressure/ Hypertension; Ischemia; Myocardial Infarction; Transient Ischemic Attack; Stenosis; Renal Impairment
9612164-2026-04265 · Received Aug 24, 2026 · Event dated May 15, 2026
Device type: Ablation Catheter, Renal Denervation (QYI)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Bradycardia; Hematoma; Low Blood Pressure/ Hypotension; Hyperkalemia
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Symplicity Spyral"[tiab]. The summary above synthesizes these.
- Data at 36 months for the Symplicity SPYRAL HTN-ON MED pilot.
Snyder EM, Sprissler R, Olson TP · Lancet · 2022Letter, Comment
- Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications.
Kandzari DE, Townsend RR, Kario K, et al. · J Am Coll Cardiol · 2023Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Indications for renal denervation in the treatment of hypertension.
Katsurada K, Kario K · Hypertens Res · 2024Review, Research Support, Non-U.S. Gov't
- Data at 36 months for the Symplicity SPYRAL HTN-ON MED pilot - Authors' reply.
Mahfoud F, Kandzari DE, Weber MA, et al. · Lancet · 2022Letter, Comment
- Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension.
Böhm M, Tsioufis K, Kandzari DE, et al. · J Am Coll Cardiol · 2021Multicenter Study, Randomized Controlled Trial
- Radio frequency-based renal denervation: a story of simplicity?
Götzinger F, Kunz M, Lauder L, et al. · Future Cardiol · 2023Review, Research Support, Non-U.S. Gov't
- Renal denervation: recent developments in clinical and preclinical research.
Drawz P, Baumann D, Dayton A · Curr Opin Nephrol Hypertens · 2023Review
- Renal denervation for the treatment of hypertension and kidney disease.
Camafort M, Ihm SH, Ruilope LM · Curr Opin Nephrol Hypertens · 2023
- Controversies related to renal artery denervation and devices.
Agwuegbo CC, Antia AU, Shamaki GR, et al. · Curr Opin Cardiol · 2024Review
- Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MED.
Kandzari DE, Mahfoud F, Townsend RR, et al. · J Am Heart Assoc · 2026Randomized Controlled Trial, Multicenter Study
- Effects of renal denervation on the incidence and severity of cardiovascular diseases.
Katsurada K, Kario K · Hypertens Res · 2024Review, Research Support, Non-U.S. Gov't
- Assessment of the safety and effectiveness of catheter-based renal denervation with the symplicity spyral system in patients with resistant hypertension: A single-center experience.
Zehir R, Doğan C, Avc A, et al. · Clin Exp Hypertens · 2026
Other devices of this type
Also filed under product code QYI.
- Paradise Ultrasound Renal Denervation System (Paradise System)Recor Medical, Inc. · PMA 2026
- Symplicity G3 Renal Denervation RF GeneratorMedtronic, Inc. · PMA 2025
- Symplicity Spyral Multi-Electrode Renal Denervation CatheterMedtronic, Inc. · PMA 2024
- ReCor Paradise® Ultrasound Renal Denervation SystemRecor Medical, Inc. · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.